Tag: magic mushrooms

Psilocybin therapy linked to reduced suicidal thoughts in people with psychiatric disorders

A new study published in Therapeutic Advances in Psychopharmacology provides evidence that psilocybin therapy may reduce suicidal ideation in adults with psychiatric conditions. The findings come from a systematic review and meta-analysis of clinical trials and suggest that the psychedelic compound, when paired with psychological support, may have a modest but measurable impact on decreasing thoughts of suicide. Although suicide attempts and deaths were not observed in these trials, the results point to the possibility that psilocybin could play a role in mental health treatment strategies aimed at reducing suicide risk.

Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, sometimes called “magic mushrooms.” It affects the brain by stimulating serotonin receptors, particularly one known to play a role in mood regulation and emotional processing. When administered in controlled clinical settings alongside therapy, psilocybin has been shown to help relieve symptoms of depression, anxiety, and some forms of addiction.

Interest in psilocybin as a therapeutic agent has grown rapidly in recent years, especially for people who do not respond to standard treatments like antidepressants or talk therapy. Some smaller studies have suggested that psilocybin therapy might also reduce suicidal ideation, a symptom common in many psychiatric conditions.

Given suicide’s widespread toll on public health, researchers wanted to evaluate whether these early signs held up across multiple trials. To do this, they examined all available randomized controlled trials that reported on suicide-related outcomes in people undergoing psilocybin therapy.

“I was inspired to investigate the usage of psilocybin therapy to help treat my patients who suffer from treatment resistant depression. As I was reading the latest clinical trials at the time, there were some reports of increasing suicidal ideation. Increasing suicidal ideation would be a risk in this vulnerable population. When I was reviewing the literature, there was not much synthesized evidence which inspired me to pursue this study,” explained study author Stanley Wong, a general psychiatry resident at the University of Toronto.

To assess the potential impact of psilocybin therapy on suicidal ideation and behaviors, the research team carried out a systematic review and meta-analysis. A systematic review collects and evaluates all relevant studies on a specific topic using a structured and transparent process. A meta-analysis goes a step further by statistically combining results from multiple studies to estimate an overall effect. This method is often used in medicine to determine how well a treatment works by comparing evidence across different settings, sample sizes, and trial designs.

Keep reading

From trips to treatments: how psychedelics could revolutionise anti-inflammatory medicine

Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential. The stigma of that era resulted in research being suppressed by drug laws, yet with mental health treatments hitting limits, scientists have returned to this controversial corner of medicine.

Substances like psilocybin (found in magic mushrooms) and ayahuasca are now being taken seriously by scientists and doctors, not for the visions they induce, but for the healing potential they possess.

Initially, this focused on treating mental health conditions like depression, where currently prescribed drugs only help a minority of patients. But these investigations have now expanded to include diseases driven by inflammation, which psychedelic drugs may help reduce by calming down the immune system.

In both human cells grown in laboratory dishes and animal studies, psychedelic drugs like DMT, LSD, and a compound called (R)-DOI can block the release of inflammatory molecules called cytokines. These protein molecules fuel conditions like rheumatoid arthritis, asthma and even depression, as well as increasing brain damage following traumatic brain injury.

Advantage over steroids

But these drugs have a considerable advantage over typical anti-inflammatory medications like steroid drugs because psychedelics appear to work without suppressing healthy immune function, which is a major problem with steroids.

Significantly, these laboratory findings are beginning to be confirmed in studies in humans. Evidence is growing that psychedelics could hold the key to managing inflammation, one of the body’s central drivers of many chronic diseases, including depression, arthritis and heart conditions.

Take psilocybin, the active ingredient in magic mushrooms. In a study involving 60 healthy participants, just one dose was enough to significantly lower levels of two key inflammatory molecules – TNF-alpha and IL-6 – over the following week.

However, not all studies have shown the same clear results. Some only had a few participants and others were complicated by the fact that some participants had previous drug experience, which could affect the results.

One big challenge with studying psychedelics in medical research is that it’s very hard to hide who got the real drug and who got a placebo. When someone has a strong psychedelic experience, it’s obvious they didn’t just take a sugar pill.

Keep reading

A single psilocybin dose rapidly reverses chronic pain and depression in mice, study finds

In a stunning breakthrough that challenges the very foundations of chronic pain treatment, researchers have discovered that a single dose of a natural compound can rapidly reverse both physical suffering and the depression that accompanies it.

Scientists at the University of Pennsylvania found that psilocybin, the active ingredient in so-called magic mushrooms, provided lasting relief from chronic pain and depression-like symptoms in mice by calming overactive brain circuits. This research, published in the journal Nature Neuroscience, offers a radical new pathway for treating the millions who suffer from the intertwined conditions of chronic pain and mental anguish.

For the 50 million Americans living with chronic pain, this discovery represents a beacon of hope beyond the dangerous and often ineffective world of opioid pharmaceuticals. The study reveals that chronic pain does not merely hurt the body but actively rewires the brain, creating a cycle of psychological suffering that intensifies the original physical pain. This vicious cycle has long been exploited by pharmaceutical companies pushing addictive painkillers that fail to address the root cause of the problem.

The research team created two types of lasting pain in mice, some with nerve damage and others with severe inflammation. Both groups developed hypersensitivity to touch and displayed behaviors mirroring profound anxiety and depression in humans. Brain imaging identified the culprit: a region called the anterior cingulate cortex, which processes both the emotional experience of pain and regulates mood, had essentially malfunctioned. Nerve cells in this area were firing 40% more than normal and refused to calm down.

Keep reading

Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows

The U.S. Department of Defense (DOD) is expanding the list of drugs that military service members will be tested for to include the psychedelic compound psilocin, one of the two main components of psilocybin mushrooms.

In a memo obtained by Marijuana Moment, a DOD employee performing the duties of the deputy under secretary of defense for personnel and readiness advised military leadership that psilocin will be added to the department’s Drug Demand Reduction Program drug testing panel effective October 1.

The memo, dated August 18, states that the policy change being made due to “the risk of impairment and subsequent deterioration of security, military fitness, readiness, good order and discipline.”

“Drug abuse by Service members is a safety and readiness issue, and the Department must adapt our detection and deterrence program to address new and emerging drug threats,” Dr. Merlynn Carson wrote.

The DOD official said that attachments to the memo lay out “cutoff concentrations” for a positive psilocin test and other drugs in the testing panel.

Marijuana Moment reached out to DOD for copies of those attachments, but representatives were not able to immediately provide the documents.

“The Department of Defense maintains a zero-tolerance policy prohibiting drug use, and we remain committed to continually expanding drug testing capabilities and enhancing our education and prevention efforts by providing effective information on drug misuse, including the use of Psilocin,” an official told Marijuana Moment in an email.

The memo says that the “first priority” for psilocin testing under the revised drug panel “will be given to specimens collected under the auspices of probable cause, consent, or command.”

“In proportion to laboratory capabilities and capacity, second priority will be given to special testing requests for other collection modes, such as routine inspection-based collections, and specimens may also be randomly tested for psilocin,” it says.

At the same time that DOD has moved to test for psilocin, it’s also carrying out a congressional mandated psychedelic therapy pilot program for active duty service members and veterans. A more recent spending bill covering DOD would require a “progress report” on that initiative.

This latest memo also comes about two months after a DOD contractor sued the federal government, alleging that questions about his past marijuana use during a security clearance process violated his Fifth Amendment right against self-incrimination.

While the latest DOD policy update concerned a psychedelic compound, questions about federal workers testing positive for marijuana have also ballooned in recent years, as more individual states have legalized the drug.

Keep reading

Single dose of psilocybin provides lasting relief from depression and anxiety in cancer patients

A clinical trial examined the effects of psilocybin combined with psychological support on cancer patients diagnosed with major depressive disorder. Results showed that a single dose of psilocybin had robust antidepressant effects in these individuals. Fifty percent demonstrated sustained depression reduction, while 43% experienced a sustained reduction in anxiety. The research was published in the journal Cancer.

Depression is a mental health condition that involves persistent sadness, loss of interest, and feelings of hopelessness. It is often accompanied by anxiety, which is characterized by excessive fear, worry, and physical tension. Both conditions are common psychological responses to the challenges of living with cancer.

Cancer patients often face uncertainty about their prognosis, undergo painful treatments, and experience changes in physical functioning, all of which can heighten anxiety. Depression may develop as a response to the emotional burden of diagnosis, fatigue, changes in body image, or loss of independence. These conditions can negatively affect treatment adherence, as patients may avoid appointments or struggle to follow medical recommendations.

Anxiety can also intensify physical symptoms such as pain, nausea, or insomnia, creating a cycle of distress. Depression may reduce motivation and energy, limiting the patient’s ability to engage in daily activities and draw on social support. Emotional distress in cancer patients is associated with a poorer quality of life and, in some studies, worse clinical outcomes.

Study author Manish Agrawal and his colleagues explored the impact of psilocybin combined with psychological support in 30 patients with cancer and a diagnosis of major depressive disorder. Some had curable, and others had incurable forms of cancer. The average age of participants was 57.5 years, and 19 were female. None were hospitalized for depression at baseline, and 61% were not receiving psychiatric medications. During the course of the study, two patients died, reducing the number of participants in the final analysis to 28.

Keep reading

Psilocybin Can ‘Maximize’ Recovery From Traumatic Brain Injury, Scientific Review Concludes

Psilocybin, a main chemical component in psychedelic mushrooms, could play a beneficial role in patients recovering from traumatic brain injury (TBI), according to a new scientific review published in the journal Brain Science.

Reviewing 29 published studies about the use of psilocybin in patients with TBI, a three-person team from Hackensack Meridian School of Medicine and Hackensack Meridian’s JFK Johnson Rehabilitation Institute concluded that assisted psilocybin use “may have benefits in TBI by reducing inflammation, promoting neuroplasticity and neuroregeneration, and alleviating associated mood disorders.”

That conclusion, along with “positive findings in related fields, like treatment for depression and addiction, highlight the necessity for more extensive clinical trials on psilocybin’s role in TBI recovery,” authors wrote.

“The research on psilocybin as a therapeutic agent shows promise for its application in TBI in theory,” the new review says, “but it requires more in-depth studies.”

The report points to psilocybin’s apparent anti-inflammatory properties and its ability to promote the production of new neurons and connections in the brain. It also says the drug’s antidepressant properties could be helpful given the comparatively high rates of depression in TBI patients.

But the new paper also flags “concerns regarding potential ‘bad trips’ and other possible side effects,” emphasizing the “need for more controlled clinical trials to establish safe and effective protocols.”

Notably, the review found no indication that classical psychedelics were associated with an increase risk of seizures, which authors said was important given the heightened incidence of seizures already associated with TBI.

Authors emphasized that federal restrictions on psilocybin limit researchers’ abilities to easily conduct trials, writing that although “decriminalization efforts in the United States are indicative of growing interest, its federal Schedule I classification limits rigorous scientific exploration.”

Overall, the paper says, “psilocybin treatment with current therapeutic practices has the potential to maximize TBI recovery, thus providing a novel method to enhance treatment for people dealing with this persistent condition.”

The research comes amid a renewed interest in psychedelics to treat mental health and medical conditions, including TBI and post-traumatic stress disorder (PSTD), especially in military veterans.

Keep reading

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Germany has become the first country in the European Union to allow legal access to a psychedelic, under certain conditions, prior to regulatory approval.

Through a newly established compassionate use program—which has received the blessing of the country’s drug regulator, the Federal Institute for Drugs and Medical Devices (BfArM)—two facilities are now able to offer psilocybin to adults with treatment-resistant depression (TRD).

Those two clinics, the Central Institute of Mental Health (CIMH, also known as ZI Mannheim) and the OVID Clinic Berlin, expect demand will far outpace capacity. There, psychiatrists will admit qualified patients to receive Filament Health’s botanical psilocybin candidate, PEX010, in the context of a broader psychiatric care protocol.

Psychedelic Alpha spoke with Gerhard Gründer, who submitted the successful application and will lead the roll-out of the compassionate use program, to learn more about this development.

Keep reading

Psychedelic Drug May Slow Aging

Could magic mushrooms hold the key to slowing down aging? New research from Georgia’s Emory University suggests they just might.

A new study has found that psilocin—a compound produced in the body after consuming psilocybin, the active ingredient in psychedelic mushrooms—extended the lifespan of human skin and lung cells in the lab by more than 50 percent.

The researchers also found that mice treated with psilocybin lived 30 percent longer—not to mention more healthily—than their peers.

“This study provides strong preclinical evidence that psilocybin may contribute to healthier aging—not just a longer lifespan, but a better quality of life in later years,” Dr. Ali John Zarrabi, Director of Psychedelic Research at Emory University’s Department of Psychiatry said in a statement.

“As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer—they experienced better aging,” added Zarrabi, who co-led the study.

As part of their study, the researchers ran the first long-term assessment of psilocybin’s systemic effects in living animals.

They treated aged, 19-month-old mice—which is something like 60–65 in human years—with an initially low psilocybin dose of 5 mg, followed by a high dose of 15 mg every month for 10 months.

The team found that psilocybin-treated mice survived around 30 percent longer than their untreated peers. Moreover, the treated mice also looked healthier for it, with better fur quality, fewer white hairs and even hair regrowth.

While psilocybin is usually studied for its mental health benefits, the findings suggest that the compound may also tackle key drivers of aging.

According to the team, the psilocybin treatments reduced oxidative stress, improved the cells’ ability to repair DNA and helped preserve the length of telomeres—the protective caps on chromosomes that guard against damage leading to diseases like cancer, neurodegeneration and heart disease.

“Most cells in the body express serotonin receptors, and this study opens a new frontier for how psilocybin could influence systemic aging processes, particularly when administered later in life,” said senior author and former Emory professor Louise Hecker in a statement.

Though psilocybin may be best known for its hallucinogenic effects on the brain, most cells in the body have serotonin receptors, suggesting it could have much wider impacts.

Keep reading

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remain enigmatic, and few studies have explored its systemic impacts. We provide the first experimental evidence that psilocin (the active metabolite of psilocybin) treatment extends cellular lifespan and psilocybin treatment promotes increased longevity in aged mice, suggesting that psilocybin may be a potent geroprotective agent.

Introduction
To date, >150 clinical studies with psilocybin have been completed or are ongoing for various clinical indications, including psychiatric (anxiety, depression, addiction), neurodegenerative (Alzheimer’s), pain, and more1,2,3. Human studies have demonstrated that a single-dose of psilocybin can improve debilitating physical and psychological symptoms—with durable effects (up to ~5 years)4,5. Despite considerable clinical evidence supporting the therapeutic benefits of psilocybin, the molecular mechanisms responsible for these impacts remain enigmatic. Studies with psilocybin have predominantly focused on neurological impacts and/or behavioral outcomes; few studies have evaluated alternative or systemic mechanisms which may also contribute to its beneficial effects. The “psilocybin-telomere hypothesis”6 postulates that psilocybin interventions may quantifiably impact telomere length, which offers a potential explanation for its efficacy across a wide range of clinical indications. This hypothesis is based on a large corpus of studies linking mental health biological aging markers6. Accumulating evidence indicate that clinical depression accelerates aging and telomere shortening7,8,9. Positive mental psychological states are associated with longer telomeres, whereas negative psychological conditions (e.g. chronic stress, anxiety, and depression) are associated with telomere attrition7,10,11,12,13. Given the clinical evidence supporting the efficacy of psilocybin for these conditions, it is plausible that psilocybin may impact telomere length. However, no prior studies have experimentally investigated the direct impact of psilocybin on biological aging.

Keep reading

Iowa Lawmaker Supporting Medical Psilocybin Bashes Bill That Would’ve Legalized Only A Synthetic Version Of The Psychedelic

An Iowa lawmaker who pushed for the passage of a bill to create a state program allowing the medicinal use of psilocybin said Gov. Kim Reynolds’s (R) decision to veto a bill pertaining to the psychoactive compound in magic mushrooms was a “great decision.”

Rep. Jeff Shipley (R-Fairfield) said rather than focus on rescheduling a synthetic version of the drug, the state should instead prioritize creating a state program legalizing the psychiatric use of naturally occurring psilocybin.

House File 383 would have allowed for the prescription and distribution of synthetic psilocybin immediately following federal approval of the drug, and mirrored a similar bill, which was signed into law, in Colorado.

The bill dealt with crystalline polymorph psilocybin, a compound commonly known as COMP360, which is a treatment developed by the biotechnology company Compass Pathways to help patients with treatment of resistant depression, post traumatic stress disorder and anorexia nervosa.

Shipley said he “condemns Compass Pathways” for its approach at creating, and patenting, a synthetic version of the “natural psilocybin that God has given us that everyone knows and loves.”

Compass Pathways declined to comment on the veto of the bill, which it lobbied in support of, and on Shipley’s comment.

Shipley’s emailed statement also apologized for his vote in favor of the bill, which passed unanimously in both the House and Senate.

“The proper legal framework is to reschedule psilocybin to schedule IV or III, and allow the relevant state regulatory boards to make it available as medicine,” Shipley said.

Reynolds, in her explanation of the veto, similarly said the state should have time to review any federal action on the synthetic version of the drug before it legalizes it at the state level.

Shipley was a vocal supporter of House File 978, which would have legalized the use of psilocybin for psychiatric treatment through a state program. The proposed program would have operated similarly to the state’s medical cannabis program.

The bill passed the House with an overwhelming majority in late April, but was not taken up by the Senate.

Keep reading